defens
biothreat
agent
requir
broadspectrum
approach
modul
innat
immun
system
might
fulfil
requir
hackett
previou
review
innat
immun
activ
broadspectrum
biodefens
strategi
identifi
sever
unresolv
question
current
articl
systemat
approach
answer
question
focus
particip
research
group
develop
technolog
team
academ
industri
particip
review
promis
agent
came
follow
conclus
feasibl
construct
biodefens
platform
combin
synergist
agent
activ
innat
immun
system
broad
rang
pathogen
basi
conserv
microbi
compon
use
nasal
spray
immun
activ
respiratori
gastrointestin
tract
like
rout
attack
might
also
possibl
includ
agent
inhibit
molecular
event
lead
septic
shock
innat
immuneactiv
agent
design
activ
tolllik
receptor
probabl
provid
protect
biothreat
pathogen
spectrum
period
rang
day
ifn
week
immunomodulatori
oligonucleotid
initi
treatment
propos
first
index
case
biosensor
alert
boost
dose
would
requir
harm
inflamm
possibl
thu
far
transient
fever
observ
autoimmun
reaction
retrovir
activ
seen
thu
far
preclin
human
trial
mani
compound
tolllik
receptor
agonist
caus
cytokin
product
subject
test
genet
polymorph
reduc
respons
ifn
african
american
subject
j
allergi
clin
immunol
bioterror
attack
requir
immedi
effect
respons
vaccin
limit
inabl
predict
pathogen
resist
prophylact
vaccin
inher
delay
adapt
immun
respons
render
inadequ
protect
bioterror
attack
innat
immun
underexplor
option
biodefens
recent
therapeut
advanc
suggest
innat
immunomodul
hold
potenti
improv
surviv
bioterror
attack
infecti
agent
numer
product
target
variou
process
innat
immun
respons
either
current
avail
move
toward
human
trial
initi
stage
develop
indepth
investig
opportun
offer
innat
immun
biodefens
current
lack
innat
immun
cell
use
pathogen
recognit
receptor
recogn
pathogen
macromolecul
provid
immedi
respons
broad
specif
pathogenassoci
molecular
pattern
system
tolllik
receptor
tlr
compris
cellsurfac
endosom
receptor
recogn
broadli
conserv
ligand
uniqu
microorgan
current
one
tlr
agonist
licens
use
human
subject
certain
viral
infect
skin
cancer
agonist
advanc
stage
clinic
develop
tlr
might
exploit
bioterror
agent
basi
mechan
action
howev
excess
activ
innat
immun
system
result
autoimmun
diseas
septic
shock
issu
focu
investig
biodefens
includ
risk
stimul
innat
immun
current
resourc
time
need
develop
produc
effect
agent
interfac
regulatori
agenc
conclus
meet
technic
document
describ
applic
particular
product
technolog
biodefens
request
collabor
independ
review
propos
evalu
compoundmechan
action
potenti
activ
likelihood
product
approv
within
year
uniqu
overal
grade
criteria
evalu
approach
publish
hackett
appli
submit
technolog
question
rais
hackett
includ
follow
prophylact
respons
broadest
rang
bacteri
viral
pathogen
long
protect
last
could
innat
immun
therapi
trigger
harm
inflamm
innat
immun
stimul
promot
autoimmun
reaction
retrovir
activ
import
factor
human
genet
polymorph
within
innat
immun
system
innat
immun
therapi
strategi
innat
immun
cell
use
pathogen
recognit
receptor
recogn
pathogen
macromolecul
promot
rapid
respons
mention
tlr
type
transmembran
endosom
express
protein
evolutionarili
conserv
identifi
key
pathogen
recognit
receptor
innat
immun
tlr
present
human
innat
immun
cell
act
cellular
signal
cascad
augment
host
immun
respons
inflamm
tlr
agonist
modifi
host
inflammatori
respons
potenti
offer
increas
protect
infect
current
tlr
agonist
licens
use
human
subject
set
microbi
infect
cancer
tailor
specif
diseas
administ
multipl
rout
microbi
ligand
recogn
tlr
constitut
express
highli
conserv
structur
molecul
less
prone
rapid
genet
mutat
thu
tlr
agonist
less
like
select
resist
strain
fig
specif
certain
tlr
might
exploit
bioterror
agent
basi
mechan
action
exampl
block
signal
recogn
bacteri
proteoglycan
recogn
viral
doublestrand
rna
recogn
bacteri
lp
lipoteicho
acid
recogn
bacteri
flagella
requir
signal
recognit
bacteri
proteoglycan
recogn
viral
singlestrand
rna
recogn
bacteri
cpg
dna
studi
macrophag
show
tlr
stimul
sustain
amplif
agonist
might
possibl
understand
natur
occur
cytokin
immun
cell
present
possibl
use
knowledg
modul
bodi
defens
ifna
ifnb
type
ifn
exhibit
antivir
activ
ifng
type
ii
ifn
play
role
bacteri
infect
ifn
perform
role
receptor
result
phosphoryl
kinas
crucial
cytokin
cascad
express
macrophag
dendrit
cell
dc
activ
modul
matur
activ
pathogen
enemi
bioterror
attack
like
target
either
respiratori
gastrointestin
tract
easili
access
extern
environ
howev
chronic
system
activ
innat
immun
system
prophylaxi
could
harm
fatal
consequ
activ
receptor
limit
time
period
local
deliveri
eg
intranas
oral
might
minim
toxic
potenti
retreat
necessari
maintain
shortterm
innat
sensit
bioterror
agent
howev
concern
tlr
agonist
activ
plasmacytoid
dc
agonist
like
induc
autoimmun
diseas
shown
number
preclin
trial
human
topic
studi
furthermor
studi
suggest
relationship
ifn
level
autoimmun
diseas
studi
must
demonstr
efficaci
also
safeti
case
tlr
product
increas
ifn
level
pharmaceut
develop
class
immun
respons
modifi
irm
act
stimul
exhibit
antivir
antineoplast
activ
human
subject
aldara
shown
benefit
human
clinic
studi
human
papillomaviru
hpv
molluscum
contagiosum
leishmaniasi
aldara
us
food
drug
administr
fda
approv
use
treatment
actin
keratos
basal
cell
carcinoma
genit
wart
pharmaceut
plan
use
compound
select
activ
use
influenza
viru
challeng
cytokin
respons
immun
outcom
measur
similar
experi
goal
plan
select
agent
eg
hantaviru
collabor
us
armi
medic
research
institut
infecti
diseas
nasal
pulmonari
deliveri
protect
influenza
well
pharmacokinet
pharmacodynam
system
treatment
also
explor
address
question
hackett
articl
follow
broad
activ
numer
pathogen
potent
antivir
activ
mous
primat
model
herp
simplex
viru
hsv
cytomegaloviru
banziviru
rift
valley
fever
influenza
west
nile
demonstr
irm
model
also
suggest
util
leishmania
listeria
mycobacterium
speci
imiquimod
current
appli
time
per
week
activ
immunomodulatori
effect
treatment
irm
model
suggest
administr
day
exposur
provid
adequ
antiinfect
protect
rare
inflammatori
side
effect
report
specif
cellmedi
autoimmun
disord
subsid
therapi
discontinu
potenti
system
side
effect
fever
possibl
conjunct
cytokin
toxic
genet
polymorph
might
play
role
respons
variabl
screen
blood
individu
demonstr
variabl
irm
respons
cytokin
product
observ
subject
fatigu
influenzalik
symptom
report
use
concern
relationship
agonist
autoimmun
diseas
howev
extens
preclin
clinic
trial
irm
autoimmun
observ
aldara
imiquimod
cream
gone
phase
iii
clinic
trial
approv
treatment
extern
genit
wart
actin
keratosi
basal
cell
carcinoma
agonist
preclin
clinic
develop
multipl
indic
includ
cervic
hpv
infect
coley
pharmaceut
group
develop
agonist
cpg
activ
innat
adapt
immun
system
three
differ
class
cpg
oligodeoxynucleotid
odn
distinguish
structur
immun
effect
aclass
also
known
type
cpg
odn
stimul
plasmacytoid
dc
secret
high
level
ifna
natur
killer
nk
cell
secret
ifng
well
monocyt
matur
function
dc
littl
bcell
stimul
convers
bclass
type
k
cpg
odn
induc
modest
ifna
product
weak
nk
cell
activ
profound
bcell
monocyt
activ
secret
igm
cclass
cpg
odn
intermedi
immun
effect
stabl
vivo
easi
formul
cpg
bclass
odn
first
odn
enter
clinic
trial
cpg
cclass
odn
recent
enter
clinic
trial
monotherapi
chronic
hcv
infect
recent
develop
type
cpg
odn
fma
cpg
odn
daniela
verthelyi
serg
beaucag
fda
alter
chemistri
allow
cpg
odn
prepar
prodrug
therebi
eas
product
beaucag
verthelyi
unpublish
data
studi
suggest
intranas
pulmonari
deliveri
might
superior
protect
inhal
pathogen
also
evid
suggest
synergi
antibiot
treatment
infect
mycobacterium
avium
clarithromycin
possibl
postexposur
efficaci
class
cpg
toler
local
system
subject
thu
far
flulik
symptom
transient
inject
site
reaction
commonli
seen
patient
receiv
mg
cclass
cpg
shown
similar
safeti
profil
clinic
trial
healthi
volunt
hcvinfect
subject
possibl
proinflammatori
activ
intranas
rout
autoimmun
diseas
describ
mice
use
cpg
odn
model
requir
administ
day
infect
newli
develop
fma
cpg
odn
backbon
thermolyt
protect
moieti
prolong
odn
activ
odn
becom
spontan
deprotect
ultim
allow
odn
act
prodrug
studi
rodent
shown
cpg
odn
immunoprotect
effect
follow
pathogen
bacteria
bacillu
anthraci
francisella
tularensi
listeria
monocytogen
klebsiella
pneumonia
mycobacterium
speci
brucella
abortu
burkholderia
mallei
burkholderia
pseudomallei
salmonella
typhi
pseudomona
aeruginosa
orientia
tsutsugamushi
virus
vaccinia
orthopox
virus
arena
ebola
venezuelan
equin
enceph
friend
leukemia
hsv
papillomaviru
cytomegaloviru
respiratori
syncyti
viru
murin
acquir
immunodefici
viru
complex
influenza
fungu
cryptococcu
neoforman
parasit
malaria
leishmania
major
toxoplasmosi
cpg
dna
innat
protect
evid
period
approxim
day
treatment
week
later
possibl
repeat
administr
extend
protect
experi
primat
restrict
protect
demonstr
thu
far
cpg
odn
type
administ
macaqu
infect
l
major
although
theoret
concern
remain
regard
possibl
agonist
therapi
could
trigger
harm
inflamm
seen
initi
clinic
trial
human
subject
concern
includ
genet
polymorph
leder
harvard
work
coley
pharmaceut
group
synergist
platform
combin
cpg
odn
doublestrand
rna
ampligen
see
later
stimul
immun
reaction
cpg
shown
posit
result
sever
human
clinic
trial
involv
total
subject
adjuv
hepat
b
flu
cancer
vaccin
treatment
melanoma
renal
cell
carcinoma
nonhodgkin
lymphoma
cutan
tcell
lymphoma
lung
cancer
cclass
cpg
odn
cpg
induc
greater
log
reduct
viral
load
among
patient
chronic
hepat
c
viru
hcv
infect
hybridon
develop
secondgener
immunomodulatori
oligonucleotid
imo
contain
synthet
stimulatori
motif
cpr
ypg
r
pg
agonist
addit
synthet
motif
imo
compos
novel
dna
structur
attach
structur
higher
stabil
exonucleas
digest
candid
oral
administr
two
end
facilit
increas
activ
imo
induc
cytokin
secret
profil
distinct
cpg
dinucleotid
basi
immun
profil
variou
cellbas
vivo
studi
includ
nonhuman
primat
imo
broadli
classifi
distinct
group
phase
clinic
trial
human
subject
shown
increas
level
cytokin
secret
includ
ifnga
subcutan
trial
human
subject
use
weekli
dose
week
doselimit
toxic
observ
evid
advers
reaction
imo
offer
potenti
innat
immun
respons
includ
local
deliveri
exposur
hybridon
address
hackett
question
follow
basi
anim
model
agonist
provid
broad
protect
bacteria
virus
h
immun
respons
agonist
produc
strong
antigenspecif
antibodi
respons
last
week
success
antigen
challeng
week
anim
imo
use
could
potenti
address
b
anthraci
yersinia
speci
variola
dengu
ebola
salmonella
speci
listeria
speci
hepat
west
nile
viru
wnv
influenza
rickettsia
rabi
sever
acut
respiratori
syndrom
sar
infect
humor
respons
last
week
imo
shown
safe
given
week
year
patient
cancer
design
induc
defin
cytokin
profil
avoid
harm
inflammatori
respons
basi
transgen
knockout
mous
model
autoimmun
reaction
might
occur
suscept
individu
observ
clinic
trial
cpgcontain
oligonucleotid
date
evid
singlenucleotid
polymorph
affect
cpg
respons
signal
one
except
might
polymorph
receptorassoci
kinas
lead
decreas
respons
innat
immunotherapi
cpg
dna
imo
share
similar
mechan
activ
lead
imo
phase
ii
trial
renal
carcinoma
phase
trial
remun
whole
kill
viru
adjuv
sever
imo
differ
immunostimulatori
properti
variou
stage
develop
preclin
studi
number
diseas
indic
includ
infecti
diseas
thymalfasin
thymosin
manufactur
sciclon
pharmaceut
synthet
analog
thymic
peptid
shown
broad
immunostimulatori
activ
vitro
vivo
result
enhanc
adapt
innat
immun
respons
evidenc
h
cell
stimul
increas
nk
cell
activ
dc
activ
current
indic
includ
hepat
b
viru
hbv
hcv
mous
model
suggest
innat
stimul
set
aspergillu
speci
infect
lead
increas
surviv
sciclon
address
hackett
question
follow
thymalfasin
might
effect
rang
infect
includ
virus
hcv
hbv
influenza
hiv
herp
fungi
candida
aspergillu
speci
bacteria
listeria
speci
pseudomona
speci
serratia
marcescen
biweekli
treatment
human
patient
year
safe
case
harm
inflamm
autoimmun
activ
seen
thousand
human
subject
treat
thymalfasin
date
effect
genet
polymorph
unknown
thymalfasin
approv
countri
phase
iii
test
unit
state
complet
year
end
recent
evid
suggest
among
tlr
airway
epitheli
cell
activ
result
greatest
increas
innat
immun
respons
hemispherx
biopharma
produc
ampligen
poli
synthet
doublestrand
rna
agonist
induc
ifn
cascad
activ
critic
enzym
kinas
adenyl
synthetas
normal
induc
ifn
mimick
doublestrand
long
cytoplasm
rna
produc
viral
infect
synergist
immun
activ
observ
ampligen
given
conjunct
ifna
ampligen
alreadi
test
virus
use
advanc
biosystem
propos
inhal
ifn
conjunct
alferon
see
later
ampligen
demonstr
recent
mediat
protect
antivir
respons
long
day
experiment
infect
coxsacki
viru
murin
model
phase
iiiii
trial
ampligen
complet
success
human
subject
chronic
fatigu
syndrom
hiv
infect
ampligen
therapi
gener
well
toler
corixa
corpor
develop
innat
immunomodul
airway
deliveri
includ
singledos
doseescal
phase
clinic
trial
intranas
deliv
moderatestrength
agonist
current
underway
treatment
allerg
rhiniti
highli
activ
synthet
agonist
induc
innat
resist
airway
challeng
viral
bacteri
pathogen
studi
mice
demonstr
enhanc
protect
immun
airway
l
monocytogen
influenza
viru
respiratori
syncyti
viru
haemophilu
influenza
resist
infect
persist
day
accompani
induct
cytokin
chemokin
defensin
type
ifn
anim
model
suggest
respons
within
hour
administr
last
week
weekli
biweekli
administr
extend
protect
without
induc
toler
protect
dose
significantli
lower
toxic
dose
suggest
safe
therapeut
index
phase
multidos
doseescal
trial
highact
agonist
schedul
earli
expect
effect
last
day
biweekli
dose
extend
durat
week
redos
might
avoid
prolong
innat
stimul
potenti
autoimmun
reaction
biweekli
intranas
deliveri
associ
system
inflamm
corixa
anticip
genet
polymorph
significantli
affect
agonist
respons
howev
recent
studi
suggest
phylogenet
individu
divers
respons
suggest
possibl
variabl
efficaci
agonist
phase
clinic
trial
recent
complet
seriou
sever
advers
event
report
addit
clinic
trial
phase
safeti
studi
phase
ii
plan
ifna
play
signific
role
innat
immun
viral
infect
also
evid
viral
decoy
mechan
wherebi
virus
develop
mechan
evad
innat
immun
multicompon
approach
ifn
treatment
could
possibl
overcom
potenti
form
innat
resist
activ
innat
immun
system
ifn
rais
safeti
issu
regard
possibl
advers
reaction
includ
microbi
reaction
seen
sarcoidlik
diseas
mice
seen
current
treatment
hepat
infect
pegyl
ifn
hemispherx
biopharma
also
produc
alferon
natur
ifna
alferonn
inject
might
soon
avail
oral
form
welldocu
safeti
record
anim
studi
suggest
oral
ifna
might
activ
much
lower
dose
administ
parenter
expect
oral
dose
time
lower
alreadi
fda
approv
parenter
administr
alferon
induc
antibodi
format
oppos
recombin
form
ifna
show
broadspectrum
antivir
activ
chronic
viral
diseas
one
benefit
alferon
might
multispeci
offer
variou
bind
affin
yield
greater
antivir
activ
question
hemispherx
intend
address
includ
dose
comparison
rout
deliveri
vivo
versu
vitro
peripher
blood
respons
potenti
refractori
period
synergi
ampligen
product
whether
alferon
render
effect
prophylaxi
hemispherx
also
develop
oragen
class
adenyl
analog
activ
part
ifn
cascad
thu
augment
innat
immun
expect
oragen
taken
combin
either
alferon
ampligen
increas
innat
protect
viral
decoy
devic
oragen
potenti
mediat
end
product
innat
immun
cascad
rnasel
activ
hemispherx
intend
address
rout
deliveri
oral
effect
prophylaxi
synergi
ampligen
alferon
inactiv
viral
decoy
mechan
oragen
hemispherx
biopharma
address
hackett
question
regard
ampligen
alferon
oragen
follow
agonist
might
provid
best
innat
immun
respons
respiratori
exposur
microbiolog
agent
basi
studi
sha
et
al
coupl
system
ifn
stimul
broadest
innat
immun
respons
system
innat
antivir
immun
expect
alferon
buccal
absorpt
ampligen
last
day
activ
secondari
activ
ifn
last
roughli
length
time
evidenc
anim
human
experi
evid
inflammatori
reaction
observ
either
ampligen
alferon
administr
dose
ampligen
result
cellmedi
autoimmun
respons
alferon
superior
singl
recombin
ifn
type
regard
bind
receptor
structur
alter
genet
polymorph
hemispherx
doubt
signific
role
genet
polymorph
ampligen
respons
basi
lack
clinic
seriou
advers
reaction
date
multival
approach
might
optim
innat
stimul
pathogen
protect
minim
advers
reaction
fda
approv
might
slow
agent
propos
combin
hemispherx
initi
alferon
ldo
studi
hivinfect
individu
studi
pattern
gene
upregul
system
circul
afg
biosolut
formerli
advanc
biosystem
suggest
use
nebul
ifn
g
form
metereddos
inhal
data
mice
demonstr
prevent
lethal
respiratori
vaccinia
infect
ifna
ifng
propos
effect
might
includ
earli
postexposur
studi
bunyavirus
arenavirus
flavivirus
coronavirus
orthomyxovirus
afg
biosolut
address
aforement
question
follow
ifn
ultim
provid
antivir
immunoregulatori
protect
induc
ligand
preexposur
prophylaxi
exogen
administr
ifn
activ
antivir
pathway
faster
tlr
ligand
might
effect
form
prevent
therapi
exposur
certain
viral
infect
anticip
durat
day
week
daili
dose
ifn
given
day
biweekli
dose
given
week
use
pegyl
ifn
side
effect
chronic
ifn
treatment
seen
thu
far
hbv
hcv
treatment
includ
flulik
symptom
fatigu
depress
nausea
weight
loss
musculoskelet
pain
leucopenia
howev
midterm
longterm
protect
administ
week
month
nontox
dose
prophylaxi
ifn
could
trigger
harm
inflamm
ifn
therapi
result
autoimmun
reaction
variou
case
report
larg
dose
ifn
smaller
dose
short
period
time
autoantibodi
serial
test
monitor
exacerb
might
limit
possibl
autoimmun
reaction
genet
polymorph
like
play
role
ifn
respons
race
appear
affect
respons
ifn
therapi
hcv
african
american
subject
reduc
respons
rel
white
subject
publish
data
cite
afg
biosolut
demonstr
safeti
aerosol
ifn
howev
indepth
evalu
treatment
infecti
diseas
human
subject
must
demonstr
literatur
use
aerosol
ifn
treatment
rhinoviru
infect
show
aerosol
ifn
result
reduct
viru
replic
littl
relief
symptom
increas
blood
nasal
secret
compar
placebo
inhal
ifn
like
similar
side
effect
current
rout
administr
might
accept
set
biothreat
agent
bta
afg
biosolut
inc
conduct
preclin
studi
ifn
prophylaxi
viral
infect
efficaci
toxic
pharmacokinet
optim
regimen
deliveri
rabbit
model
nmrccelsci
suggest
strategi
enhanc
innat
immun
respons
pathogen
exposur
synthet
peptid
contain
amino
acid
sequenc
deriv
b
chain
mhc
class
ii
stimul
h
respons
numer
infecti
agent
administr
result
increas
serum
ifng
level
number
ifng
cell
antimalaria
state
water
solubl
administ
subcutan
intramuscular
oral
rout
mous
model
suggest
prophylact
protect
plasmodium
yoelii
leishmania
major
arboenceph
viru
nmrccelscineoucom
address
question
follow
shown
mice
induc
protect
divers
microbi
infect
parasit
viral
molecul
cell
cell
leav
state
readi
h
respons
infecti
challeng
mous
studi
suggest
protect
lethal
week
intramuscularli
oral
month
subcutan
administr
given
day
infect
malaria
model
suggest
durat
sever
month
protect
present
day
singl
inject
two
inject
induc
complet
protect
within
week
decreas
month
sign
harm
inflamm
observ
anim
model
evid
suggest
promot
autoimmun
reaction
retrovir
activ
detect
antibodi
mous
cell
blood
spleen
liver
found
administr
possibl
genet
polymorph
might
affect
respons
evid
found
mice
defect
receptor
prone
h
respons
unabl
complet
protect
plasmodium
yoelii
earli
stage
develop
thu
mani
unansw
question
regard
safeti
human
subject
therapeut
rang
sciclon
propos
use
dipeptid
immunomodul
origin
develop
russia
stimul
innat
immun
system
set
bta
appear
stimul
macrocyt
phagocytosi
h
cytokin
use
demonstr
bacteria
tuberculosi
virus
pichind
hpv
current
administ
subcutan
oral
dosag
form
bioavail
durat
expect
week
month
case
harm
inflamm
autoimmun
reaction
retrovir
activ
seen
anim
hundr
human
subject
treat
date
effect
genet
polymorph
yet
evalu
regard
respons
approv
use
russia
phase
test
unit
state
tlr
signal
transduct
might
essenti
trigger
fatal
sepsi
cascad
kevin
tracey
colleagu
propos
compound
antihigh
mobil
group
box
antibodi
counter
septic
shock
late
cytokin
produc
activ
macrophag
mediat
lethal
sepsi
anim
lethal
infect
also
releas
tissu
increas
organ
damag
antibodi
shown
prevent
death
anim
model
inhibit
activ
disrupt
epitheli
cell
organ
tracey
colleagu
current
investig
possibl
express
cholinerg
agonist
respons
acetylcholin
agonist
small
molecul
prevent
overproduct
cytokin
like
tnf
accomplish
target
receptor
macrophag
turn
inhibit
nuclear
factor
kb
activ
cytokin
regul
respons
releas
lethal
cytokin
tnf
block
alreadi
shown
prevent
death
caus
periton
support
possibl
role
lethal
infect
like
antibodi
enter
clinic
trial
within
month
treatment
expect
last
week
suppress
cytokin
overproduct
last
day
week
compound
appear
effect
exposur
diseas
onset
safeti
yet
determin
human
genet
polymorph
could
play
role
shock
modul
patient
might
genet
predisposit
overexpress
tnf
wherea
other
might
low
level
tnf
high
level
ifng
increas
tnf
activ
webster
sternberg
nation
institut
mental
healthnat
institut
health
propos
use
drug
select
gener
categori
agent
target
central
nervou
system
potenti
novel
way
inhibit
bacteri
shock
sever
arm
central
nervou
system
known
regul
immun
respons
includ
hypothalamicpituitaryadren
axi
sympathet
nervou
system
parasympathet
nervou
system
peripher
nervou
system
mani
agent
categori
alreadi
avail
reach
earli
clinic
trial
current
develop
purpos
bta
defens
suggest
good
possibl
approv
year
fig
review
literatur
submit
propos
suggest
follow
respons
hackett
question
theori
broadli
activ
immunopotenti
yield
broadest
protect
respons
candid
innat
immun
receptor
activ
includ
h
ifna
ifng
receptor
concern
exist
variabl
express
target
small
anim
model
human
model
eg
human
subject
express
wherea
mice
express
much
greater
varieti
cell
type
thu
correl
efficaci
durat
seen
anim
model
must
take
account
speciesspecif
differ
accur
repres
human
respons
immunomodul
like
rout
attack
respiratori
gastrointestin
probabl
ideal
rout
protect
minim
drug
exposur
innat
immun
rel
brief
durat
especi
absenc
activ
threat
stimulu
protect
immunomodul
usual
last
week
regardless
mechan
target
potenti
readministr
extend
protect
effect
greater
week
exact
durat
vari
mechan
action
deliveri
method
advers
effect
chronic
use
enhanc
innat
immun
carri
inher
risk
inflammatori
respons
immunomodul
agonist
rais
concern
possibl
innat
overact
basi
pivot
role
develop
septic
shock
individu
prone
autoimmun
reaction
retrovir
activ
innat
immunomodul
becom
increasingli
like
target
yield
polyclon
bcell
activ
ie
agonist
increas
likelihood
loss
selftoler
develop
autoantibodi
also
concern
possibl
relationship
ifn
autoimmun
remain
establish
genet
polymorph
import
potenti
variabl
depend
molecular
target
select
therapi
better
comprehens
genet
variabl
could
lead
improv
treatment
nonrespond
discoveri
novel
target
innat
immunomodul
could
affect
advers
event
inflammatori
respons
predispos
individu
